SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2021 / NephroSant, a kidney health company from UC San Francisco, today announced that it has completed its $ 16 million oversubscribed Series A funding round. DaVita Company Group led the investment cycle, with input from DigitalDx Ventures and other previous investors. The funding will be used to support research and development and the launch of NephroSant’s first product: Qsant â¢, a needle-free urine test that helps determine if a patient’s body is rejecting a transplanted kidney.
âWe are very excited to be working with DaVita, a recognized leader in kidney care,â said Dr. Minnie Sarwal, CEO and Founder of NephroSant, as well as Professor of Surgery at UCSF. âTheir expertise and experience perfectly complements NephroSant’s vision and goal to redefine kidney health. “
Qsant â¢ is the first home urine test designed specifically for the detection of kidney transplant rejection, without the need for an expensive and invasive biopsy. This test uses several biomarkers, including proprietary technology for measuring cell-free DNA in urine. Currently, up to 40% of all kidney transplant recipients result in clinical or subclinical rejection. Identifying and predicting rejection earlier will allow clinicians to intervene earlier and help patients live longer.
âTransforming kidney care requires bold innovation, which is precisely why DaVita Venture Group invested in NephroSant and its breakthrough solution that helps patients manage their transplanted kidney health,â said Dr. Jeff Giullian, Director medical from DaVita. âAs a transplant nephrologist, I look forward to a future where patients not only have better access to a transplant, but can also extend the life of a transplant with Qsant â¢. “
By giving the patient the option of a home sample collection method, Qsant â¢ improves patient convenience and safety, which is especially important in the context of the current COVID-19 pandemic. In addition, Qsant â¢ requires a single urination of urine instead of a 24 hour urine collection. Qsant â¢ uses a proprietary algorithm to generate a unique quantitative rejection risk for each patient, called “patient personalized”Q-Score.“
âAs Nephrosant’s first institutional investor, we are honored to welcome DaVita Venture Group and follow them in this next round of funding,â said Michele Colucci, Founder and Managing Partner of DigitalDx Ventures. âDr. Minnie Sarwal’s non-invasive urine tests for kidney health and transplant rejection are revolutionary, combining a patient-centered approach and exceptional precision. We are very fortunate to be able to support this incredible founder and to play a essential role on the board of directors as we pursue our mission of making quality health care more accessible to all. â
NephroSant is a physician-founded rapid diagnostics startup, with a world-class team of scientists, engineers and clinicians, focused on applying the founding team’s years of clinical research expertise to improve health. global renal. Our mission is to translate in-depth scientific and pathological knowledge into first-rate non-invasive tests to combat the hidden epidemic of chronic kidney disease, which affects more than 10% of the adult population worldwide, through a growing range of products. Nephrosant was created from Sarwal Lab, UCSF. To learn more, visit nephrosant.com.
About DaVita Inc.
DaVita (NYSE: DVA) is a healthcare provider focused on transforming the delivery of care to improve the quality of life for patients around the world. The company is one of the largest providers of kidney care services in the United States and has been a leader in clinical quality and innovation for over 20 years. Through DaVita Kidney Care, the company treats patients with chronic kidney disease and end-stage kidney disease. DaVita is committed to adopting bold, patient-centered care models, implementing the latest technologies and evolving towards integrated care offerings for all. Through these efforts, DaVita has also become the largest home dialysis provider in the country. As of December 31, 2020, DaVita served 204,200 patients at 2,816 outpatient dialysis centers in the United States. The company also operated 321 outpatient dialysis centers in 10 countries around the world. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to a high-quality, equitable standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
THE SOURCE: Nephrosis
See the source version on accesswire.com: